about
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyChromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsPersistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaNew recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classificationMutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreSPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemiaHigh Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionCore-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
P50
Q27851679-9FBE0BAB-A3ED-47EC-843D-BD236E4DC363Q27851713-A32EA856-7AF3-4615-9FB7-CBA93AA7D831Q27851839-4FF6310C-5861-4BAE-A700-9B62053FBD31Q33717707-F2B52F73-BD14-4D1F-A5F7-8B74731FEADDQ33822055-3D20AC70-A2DC-46C4-ACA4-90752CE78467Q34119417-732A2084-892A-4121-A0FC-AE40FD3B71C5Q34314927-1D7D4622-6F85-4AAE-93E3-E929E998338AQ34831106-D49E3A35-5D5C-4FF3-A044-F56D8D7199FAQ35004970-076476F7-1DCB-4B15-BDE8-FC5B7BF4C666Q35265946-5B4446BE-A55B-4459-8DAA-5B3899C80595Q35794120-E0AD57CF-1325-4F6E-87B1-446468DFFD22Q36457184-8A45137D-F8D5-4940-AEB7-D445FAE68A0EQ36529502-0CD72DF2-1DDF-4B11-ADA9-E3191D739024Q37065843-C2168C5F-3630-4292-848A-A9BEF043F248Q37338371-7840FC57-C511-473E-99DF-3BA6FCD250B8Q37408629-A69B80D0-795C-466F-B569-CD9D786D67D9Q37418318-33A89629-EB2C-4226-8D49-5695BC99D0F2Q37483972-16280676-49BB-4760-AEF3-DB6585D37333Q37552031-B6950535-EEE5-40E8-B1D3-68525F9B7B4CQ37560138-85434282-5252-470D-8D65-BC7C21519AB2Q37570427-0BC34EF9-B62C-4685-8BE0-8E3647067814Q37679943-6A682904-F34A-4084-AB1E-C37295228852Q38377189-0FBD6C30-546B-4EA7-BC06-E9DC2EF2C877Q42720673-BAD32084-E088-4BD7-8AB9-B89E08203B2CQ43065871-21AE1755-378D-4F83-B37C-E2EF4DB9F09BQ52347210-9B26756F-3415-47FF-9E8D-1462FC19A40EQ57898894-FCC6D5F9-EFC4-46B0-B3EE-D0443ED72AA3Q58772579-4800E0F4-C0E7-40EF-AE9A-19623AFD0AA1Q60300719-7F46DC96-E06C-4D1E-9B86-0ACB44DBBE92Q64124360-7344B641-EE62-44CF-9E97-278E720661A3
P50
name
Jessica Kohlschmidt
@ast
Jessica Kohlschmidt
@en
Jessica Kohlschmidt
@nl
type
label
Jessica Kohlschmidt
@ast
Jessica Kohlschmidt
@en
Jessica Kohlschmidt
@nl
prefLabel
Jessica Kohlschmidt
@ast
Jessica Kohlschmidt
@en
Jessica Kohlschmidt
@nl